Project Grant R01HL183201
Award Date 8/15/26
Completion Date 4/30/30
Dollars Obligated $766K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Florida $688,383 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to support preclinical and translational research on mitochondrial efficiency in peripheral artery disease. The project, titled "Enhancing OXPHOS Efficiency to Promote Muscle Function and Regeneration in Peripheral Artery Disease," will develop strategies to optimize leg muscle oxidative metabolism in PAD...
- The National Heart, Lung, and Blood Institute awarded New York University $872,787 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct proteomic discovery and validation research on chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease. The award funds development of proteomic signatures to predict major adverse limb events (MALE) and major adverse cardiovascular events (MACE) in CLTI patients, and to guide...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $618,352 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanical regulation of endothelial lipid droplet metabolism and its role in vascular dysfunction. The research examines how oscillatory shear stress suppresses triglyceride hydrolysis by inactivating the transcription factor FOXO1, leading to lipid droplet accumulation in...
- The National Heart, Lung, and Blood Institute awarded Research Institute At Nationwide Children's Hospital $1,326,945 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a translatable molecular imaging paradigm for comprehensive assessment of peripheral artery disease (PAD). The recipient will characterize stages of peripheral atherosclerosis using dual-phase PET/CT imaging with fluorine-18 sodium fluoride (18F-NAF) to quantify both regional muscle...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $776,745 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and target DELE1-mediated mitochondrial stress signaling in cardiomyopathy. The research addresses how mitochondrial dysfunction drives cardiovascular disease, including heart failure and ischemic injury, by characterizing the molecular mechanisms through which DELE1 acts as a mitochondrial stress sensor to...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $756,607 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research leveraging nutrient sensing and lysosomal degradative capacity in macrophages as a therapeutic approach to cardiovascular disease. The project addresses atherosclerosis, the underlying cause of myocardial infarction, strokes, and heart failure, by investigating dysfunction in the autophagy-lysosome system...
- The National Heart, Lung, and Blood Institute awarded The Johns Hopkins University $776,005 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to fund research on beta-hydroxybutyrate–mediated endothelial cell and skeletal muscle dysfunction in pulmonary arterial hypertension. The project, R01HL184469, runs through May 31, 2031, with work performed in Baltimore, Maryland. The research addresses the mechanisms linking mitochondrial dysfunction in lung...
- The National Heart, Lung, and Blood Institute awarded Albany Medical College $586,474 under CFDA 93.837 (Cardiovascular Diseases Research) on June 15, 2026, to investigate lipolytic sterol signaling mechanisms in foam cell modulation and atherosclerosis prevention. The project targets lipid droplet-associated hydrolase (LDAH) as a regulator of adaptive responses to lipid overload in atherosclerotic lesions. Research will examine how LDAH mobilizes sterol stores within cytoplasmic lipid...
- The National Heart, Lung, and Blood Institute awarded University of Massachusetts Medical School $103,686 on December 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support basic research into translation control mechanisms in heart and lung disease. The funded research investigates how the RNase A family nuclease angiogenin stimulates blood vessel formation and why angiogenin dysfunction associates with heart failure, and separately examines how the bacterial...
- The National Heart, Lung, and Blood Institute awarded Duke University $778,772 on August 18, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate metabolic and contractile dysfunction in heart failure with preserved ejection fraction. The research focuses on understanding the mechanistic link between mitochondrial impairment and loss of muscle strength and power in HFPEF, a systemic disorder affecting 3–4 million U.S. patients predominantly older women. The...